Vilanterol trifenatate for the treatment of COPD

Malerba, Mario; Radaeli, Alessandro; Montuschi, Paolo; Morjaria, Jaymin B.

doi:10.1080/17476348.2016.1184976

Cited by 12 publications

(10 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it also displays persistent agonist action as well as reassertion behavior at the β 2 -AR in recombinant cells and guinea pig trachea [41,42]. The exact mechanism of the persistence in VI and previous long-acting β 2 -AR agonist remains unknown.…”

Section: Potency and Onset Of Actionmentioning

confidence: 94%

Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma

Chang

Gray

Thomas

2016

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

FF has a highly specific, fast association and slow dissociation from the glucocorticoid receptor, with a 24 hr duration of action. This, combined with a slow transport out of respiratory cells, creates a long tissue retention period. Vilanterol trifenate (VI) is a new inhaled, selective, long - acting β2 adrenergic agonist, also with a rapid onset of action with a maximal effect within 6 mins and prolonged lung retention with effects on lung function over 24 hours. Expert commentary: Multiple Phase I-III efficacy studies performed on FF and VI have shown an improvement in spirometry as well as symptom control in asthma. The development of once daily ICS/LABA combinations may potentially improve adherence to asthma therapy, but this has yet to be demonstrated.

show abstract

Section: Potency and Onset Of Actionmentioning

confidence: 94%

Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma

Chang

Gray

Thomas

2016

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…Vilanterol is a novel highly selective long acting beta2‐adrenergic agonist (LABA) with bronchodilatory effects lasting for 24 hours . The pharmacologic effects of be β 2‐Adrenoceptor ( β 2‐AR) agonists, including vilanterol, play a major role in the management of COPD by increasing airflow into the lungs via relaxation of the airways .…”

Section: Pharmacodynamic and Pharmacokinetic Propertiesmentioning

confidence: 99%

Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review

Ramadan

Masri²,

Rizk³

2019

Clinical Respiratory J

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a common respiratory disease that is predicted to be one of the leading causes of death worldwide. Pharmacologic treatment options of COPD are bronchodilators, using either long‐acting β2‐agonists (LABAs), or long‐acting muscarinic antagonists (LAMAs), or a combination of two. Anoro Ellipta (umeclidinium + vilanterol) dry powder inhaler, a fixed‐dose combination of LAMA and LABA, was Food and Drug Administration (FDA) approved in 2013 for COPD. The objective of this study is to evaluate the efficacy and safety of once daily umeclidinium/vilanterol (62.5 mcg/25 mcg) in COPD patients, focusing on pharmacodynamic and pharmacokinetic characteristics, efficacy and safety in clinical studies and cost. Literature search was done through PubMed (2004‐2017) using the terms umeclidinium, vilanterol, COPD, LABA and LAMA. Recent and significant clinical trials about the monocomponents and their combination were identified, in addition to reviews, guidelines for COPD, data from manufacturer and FDA product labels. The search was limited to English language studies on human subjects. Clinical data published on the combination of umeclidinium/vilanterol in patients with COPD have shown greater improvements in lung function compared to monotherapies. However, further studies comparing umeclidinium/vilanterol FDC (ANORO) to other LABA/LAMA combinations are needed.

show abstract

“… 33 In a DPI FDC with fluticasone furoate 100 µg, vilanterol 25 µg is approved for once-daily maintenance treatment of COPD. 34 For once-daily treatment of persistent asthma, vilanterol 25 µg is approved in two strengths of fluticasone furoate (100 µg and 200 µg). Unlike other once-daily LABA, including indacaterol and olodaterol, vilanterol was not developed for monotherapy of COPD.…”

Section: Fluticasone Umeclidinium and Vilanterol For Copdmentioning

confidence: 99%

“…Unlike other once-daily LABA, including indacaterol and olodaterol, vilanterol was not developed for monotherapy of COPD. 33 , 34 …”

Section: Fluticasone Umeclidinium and Vilanterol For Copdmentioning

confidence: 99%

Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects

Malerba

Nardin

Santini

et al. 2018

Ther Adv Respir Dis

Self Cite

View full text Add to dashboard Cite

Maintenance pharmacological treatment for stable chronic obstructive pulmonary disease (COPD) is based on inhaled drugs, including long-acting muscarinic receptor antagonists (LAMA), long-acting β2-adrenoceptor agonists (LABA) and inhaled corticosteroids (ICS). Inhaled pharmacological treatment can improve patients’ daily symptoms and reduce decline of pulmonary function and acute exacerbation rate. Treatment with all three inhaled drug classes is reserved for selected, more severe, patients with COPD when symptoms are not sufficiently controlled by dual LABA/LAMA therapy and exacerbations are frequent. This review focuses on the role of single-inhaler triple therapy with once-daily fluticasone furoate/umeclidinium/vilanterol fixed-dose combination, which is in phase III clinical development for maintenance treatment of severe-to-very severe COPD. In this review, we summarize evidence providing the rationale for its use in COPD and discuss the gaps to be filled in this pharmacotherapeutic area.

show abstract

Vilanterol trifenatate for the treatment of COPD

Cited by 12 publications

References 60 publications

Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma

Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma

Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review

Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects

Contact Info

Product

Resources

About